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Research
The physiologic estrogens estradiol (E2), estrone 
(E1), and estriol (E3) play important and selec-
tive roles in different life stages of women. E2 is 
the predominant form driving sexual develop-
ment and function of reproductive organs (e.g., 
breast and uterus) and the menstrual cycle. E1 
and E3 have important physiologic functions 
at discrete life stages such as pregnancy, and 
E1 is a major estrogen in the post  menopausal 
phase. These estrogens are produced mainly 
in the ovaries and in the placenta, although 
small amounts are also produced by the adre-
nal glands and brain (Lippert et al. 2003; 
Reddy 1979). Some E1 is made in most tissues, 
but especially in fat and muscle, which are a 
major source of estrogens in post  menopausal 
women. All of these physiologic estrogens may 
also affect the brain, bone, cardio  vascular sys-
tem, and many other tissues (Cornwell et al. 
2004). Although important for physio  logic 
control of female develop  ment and repro-
duction, and the coordination of many other 
tissues and organ systems to support repro-
duction, estrogens are also associated with the 
development of cancers of estrogen-responsive   
tissues such as breast, uterus, and pituitary. 
Therefore, it is important to understand mech-
anisms that affect the balance between these 
beneficial versus detrimental roles of estrogens.
Mitogen-activated protein kinases 
(MAPKs), including extracellular-signal– 
regulated kinases (ERKs), play central roles 
in controlling such diverse cellular out-
comes as cell proliferation, apoptosis, and 
maturation to perform distinct functional 
roles. Such kinases can also influence whether 
cells proliferate excessively and develop into 
tumors. Many different stimuli, including 
steroids, growth factors, cytokines, ligands for 
G-protein–coupled receptors, and carcino-
gens, can activate the ERK pathways; ERKs 
can therefore serve as signal integrators for 
all of these inputs (Watson et al. 2010), so 
that the cell can render a final decision about 
its overall destiny (cell division, differentia-
tion, death, or malignant transformation). 
The contribution of physiologic estrogens to 
this signaling mixture, integrated by MAPKs, 
can also be influenced by estrogens that signal 
inappropriately, such as xeno  estrogens (XEs).
In a rat pituitary cancer cell subline 
(GH3/B6/F10) that we selected for its nat-
urally high levels of membrane estrogen 
receptor-α (mERα) expression (Pappas et al. 
1994), treatment with E2 can activate ERKs 
and also cause prolactin release within a few 
minutes, elicited in part by calcium influx 
within seconds (Bulayeva et al. 2004, 2005; 
Norfleet et al. 2000; Pappas et al. 1995a). 
Rapid inductions of ERK phosphorylation 
by E2 are contributed to by many different 
upstream signaling pathways, with signals 
traveling down their cascades at varying speeds 
(Belcheva and Coscia 2002; Bulayeva et al. 
2004). Although the less studied physiologic 
estrogens E1 and E3 have weak effects on tran-
scription (Kuiper et al. 1997; Lippman et al. 
1977), they are as effective as E2 in causing 
ERK phosphorylation and other non  genomic 
responses in pituitary, breast, uterine, and 
neuronal cells (Alyea and Watson 2009b; 
Kabil et al. 2008; Mermelstein et al. 1996; 
Raz et al. 2008; Watson et al. 2008; Zhang 
et al. 2009). In the present study we address 
the inter  action of physiologic estrogens and 
alkylphenol-class XEs on ERK activation.
Environmental estrogens are manufactured 
products that contaminate food, water, or air to 
which humans and animals are exposed (Foster 
2008; Sonnenschein and Soto 1998; Tapiero 
et al. 2002). The alkyl  phenols are a structur-
ally related (and therefore interesting to com-
pare mechanistically) set of such compounds; 
they vary in their carbon side-chain length 
or, in the case of bisphenol A (BPA), have a 
phenol group instead of an alkyl side chain 
[see Supplemental Material (doi:10.1289/
ehp.1002512)]. Alkylphenols are wide  spread 
industrial surfactants (Burback and Perry 1993; 
Kolpin et al. 2002; White et al. 1994), whereas 
BPA is ubiquitous because it is a precursor 
and breakdown product of the commonly 
used poly  carbonate plastics (Tsai 2006). Many 
environ  mental estrogens readily accumulate 
in the environment and in animal tissues and 
have been shown to affect both reproductive 
and non  reproductive organs/systems in ani-
mals and humans (Han et al. 2004; Hossaini 
et al. 2001; Moon et al. 2007; Tsai 2006). 
Although the genomic effects of these environ-
mental estrogens have been studied extensively 
and found to be weak (causing government 
regulatory agencies to consider them “safe”), 
until recently little was known about their 
non  genomic estrogenic effects. Environmental 
estrogens produce potent membrane-initiated 
signaling effects similar but not identical to 
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those elicited by E2 (Alyea and Watson 2009a; 
Bulayeva and Watson 2004; Kabil et al. 2008; 
Wozniak et al. 2005; Zsarnovszky et al. 2005). 
A prominent charac  teristic that has greatly con-
tributed to the confusion over their toxicity is 
the non  monotonic concentration dependence 
of their non  genomic responses (Palanza et al. 
2001; Vandenberg et al. 2006; Watson et al. 
2010). Environmental estrogens are suspected 
of affecting a wide variety of functions by inter-
fering with the actions of physiologic estrogens, 
but sufficiently sensitive techniques for quanti-
tative documentation of these disruptions have 
generally been lacking.
In the present study, we examined 
whether diverse physiologic estrogens and XEs 
[whose structures are shown in Supplemental 
Material (doi:10.1289/ehp.  1002512)] can 
disrupt physiologic estrogen signaling via 
ERKs when in combination. We studied all 
compounds at a wide range of low concentra-
tions and at multiple time points because we 
expected variations in both their concentra-
tion dependence and response progression. 
We then examined which estrogen recep-
tor (ER) subtypes participate in these ERK 
and proliferation responses. We used fixed 
cell-based immuno  assays that allowed us to 
analyze many conditions simultaneously. 
By examining these mER-mediated cellu  lar 
responses leading to the integrated activation 
of ERKs, we hoped to better understand the 
endocrine-disrupting impact of the alkyl-
phenol class of environmental XEs.
Materials and Methods
Materials and cell culture. We purchased 
phenol red-free Dulbecco’s modified Eagle 
medium (DMEM; high glucose) from 
Mediatech (Herndon, VA), horse serum from 
Gibco BRL (Grand Island, NY), and defined 
supplemented calf and fetal bovine sera from 
Hyclone (Logan, UT). Paraformaldehyde 
and picric acid were purchased from Fisher 
Scientific (Pittsburgh, PA). The antibody used 
to measure phosphorylated ERKs 1 and 2 was 
purchased from Cell Signaling Technology 
(Danvers, MA), and the ERα-selective agonist 
4,4´,4″-[4-propyl-[1H]-pyrazole-1,3,5-triyl] 
trisphenol (PPT) and the ERβ-selective ago-
nist 2,3-bis[4-hydroxyphenyl]-propionitrile 
(DPN) were purchased from Tocris (Ballwin, 
MO). The G-protein–coupled ER (GPER) 
agonist G1 was a gift from Chemdiv Inc. 
(San Diego, CA) arranged by E. Prossnitz. 
Pertussis toxin, nystatin, BPA, 4-n-ethylphe-
nol (EP), 4-n-propylphenol (PP), 4-n-oc-
tylphenol (OP), 4-n-nonylphenol (NP), and 
other chemicals were purchased from Sigma 
(St. Louis, MO). GH3/B6/F10 cells were 
routinely propagated in DMEM containing 
12.5% horse serum, 2.5% defined supple-
mented calf serum, and 1.5% fetal calf serum. 
Cells were used between passages 10 and 20.
Quantitative ERK phosphorylation assays. 
We developed this assay to assess levels of acti-
vated ERKs 1 and 2 in fixed GH3/B6/F10 cells 
(Bulayeva et al. 2004). Briefly, cells were plated 
at 10,000 cells/poly-d-lysine–coated well in 
96-well plates. The next day growth medium 
was replaced with DMEM containing 1% 
charcoal-stripped (4×) serum for 48 hr. Washed 
cells were then treated with different estrogenic 
compounds for 5 min. For receptor subtype 
identification, we treated cells with ERα versus 
ERβ versus GPER analogs for 5 min before 
assay of phosphorylated ERK (pERK). We 
routinely used 20 nM phorbol 12-myristate 
13-acetate (TPA) as a positive control to 
demon  strate maxi  mum activation of ERKs via 
the protein kinase C pathway; for comparison, 
activation by E2 generally achieved 85% of the 
activation levels by TPA. The cells were then 
fixed with 2% paraformaldehyde/0.2% picric 
acid at 4°C for 48 hr and then permeabilized 
with phosphate-buffered saline (PBS) contain-
ing 2% bovine serum albumin (BSA)/0.1% 
Triton X-100 for 1 hr at room temperature. 
Cells were then washed three times with PBS 
and treated with primary antibody against 
pERKs (p-Thr202/Tyr204; 1:400 in PBS/1% 
BSA). After overnight incubation at 4°C, 
Figure 1. Time-dependent changes in pERK elicited by combinations of short-chain alkyl  phenols with E2, 
E1, or E3. GH3/B6/F10 cells were cotreated with 1 nM EP (A–C) or PP (D–F) and 1 nM E2 (A,D), E1 (B,E), or 
E3 (C,F). The pERK levels were meas  ured by plate immuno  assay after different times of cotreatment. 
*p < 0.05 compared with vehicle-treated control cells, shaded to match each set of data symbols (*, *, ✫). #p < 0.05 com-
pared with cells treated with 1 nM E2, E1, or E3 alone.
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the cells were processed for signal develop-
ment with the Vectastain ABC kit (Vector 
Laboratories, Burlingame, CA) following man-
ufacturer recommendations. Biotin-conjugated 
secondary antibody was used at a 1:300 dilu-
tion. Plates were incubated in the dark for 
20 min at 37°C for the generation of alkaline 
phosphatase product (para-nitrophenol) and 
then read at A405 in a model 1420 Wallace 
microplate reader (Perkin Elmer, Waltham, 
MA). We used the crystal violet assay to esti-
mate the number of cells in each well for signal 
normalization. Experiments were repeated at 
least two to three times using different passages 
of cells on different days.
Crystal violet assay. After ERK assays, 
the quantitative immuno  assay reagents were 
washed from the multi  well plates and the 
cells were stained with 0.1% crystal violet 
for 30 min, destained with deionized water, 
and extracted (10% acetic acid) following the 
method of Lottering et al. (1992). The A590 
signal of the extract was read in a model 1420 
Wallace microplate reader. This assay was also 
used for proliferation studies to approximate 
cell number.
Statistics. Data from pERK studies were 
analyzed by one-way analysis of variance fol-
lowed by multiple comparisons with the con-
trol group (Holm–Sidak method) using Sigma 
Stat (version 3; Systat Software Inc., Chicago, 
IL). Significance was accepted at p < 0.05.
Results
Because women are exposed to environ  mental 
estrogens during life phases when different 
physiologic estrogens are prevalent, we stud-
ied the changes in pERK when each physi-
ologic and environmental estrogen was present 
simultaneously. We previously detailed ERK 
(and other) responses of these cells to the 
physio  logic estrogens E1, E2, and E3 (Watson 
et al. 2008); those data can be directly com-
pared with results of the present study. First, 
we examined the time-dependent changes in 
ERKs (Figures 1–3), showing that estrogenic 
stimulation caused a characteristic oscillating 
pattern with immediate (5 min), intermediate 
(10–30 min), and long-term (after 30 min) 
rises in ERK activation, similar to estrogen-
induced fluctuations we reported previously 
(Bulayeva et al. 2004; Bulayeva and Watson 
2004; Jeng et al. 2009; Jeng and Watson 
2009; Kochukov et al. 2009; Zivadinovic and 
Watson 2005). We observed these oscillating 
patterns for all estrogens, although some were 
“trends” with peaks that did not achieve signif-
icance. The physiologic estrogens E2 and E1, as 
well as BPA, tended to cause three oscillations 
during this 60-min time frame, whereas alkyl-
phenols and E3 caused only two (missing the 
intermediate peak).
When pituitary cells were cotreated with 
XEs plus each of the physiologic estrogens (E2, 
E1, or E3) in combination, the usual 2.5- to 
5-min pERK peak caused by individual estro-
gens was often abolished or blunted. Instead, 
the combination of compounds usually caused 
a pronounced early dephosphorylation and 
then created a new time-delayed, augmented 
phosphorylation peak, just as the actions of 
individual estrogens waned. These new large 
activations (although a bit smaller in the PP, 
OP, and NP combinations with E3) peaked 
instead in the intermediate 10- to 30-min time 
frame, demon  strating how combinations of 
estrogens with XEs that individually do not 
elicit a significant response at a given time 
point can cause a synergistic response. Then, 
as the ERK activation induced by individual 
estrogens again rose at 60 min, the level due 
to the combined estrogens usually declined, 
often far below the response to the individual 
estrogens. (The exceptions to this observation 
were combinations of PP plus E2 and 10–9 M 
BPA plus E1 or E2, when the intermediate 
pERK peak was sustained.) Although the later 
(30–60 min) response period was usually inhib-
ited, it depended somewhat on the efficacy of 
the XE at that time point. That is, stronger 
individual XE responses (resembling physio  logic 
estrogen responses) tended to predict the abil-
ity of the XE to inhibit the actions of physio-
logic estrogens when in combination. Thus, a 
Figure 2. Time-dependent changes in pERK elicited by combinations of long-chain alkylphenols with E2, 
E1, or E3. GH3/B6/F10 cells were cotreated with 1 nM OP (A–C) or NP (D–F) and 1 nM E2 (A,D), E1 (B,E), or 
E3 (C,F). The pERK levels were meas  ured by plate immuno  assay after different times of cotreatment. 
*p < 0.05 compared with vehicle-treated control cells, shaded to match each set of data symbols (*, *). #p < 0.05 compared 
with cells treated with 1 nM E2, E1, or E3 alone.
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three-peaked oscillation caused by physiologic 
estrogens was transformed to a single major 
intermediate peak of activation in most cases. 
We used two doses of BPA to deter-
mine the effects on ERK activation caused 
by physio  logic estrogens (Figure 3) in our 
temporal phase studies because BPA is a com-
pound of high interest to the endocrine toxi-
cology community due to its ubiquity and the 
controversy about its potential effects, and 
because both of the chosen concentrations 
are in the range of typical and prevalent expo-
sures. More important, many estrogens, espe-
cially BPA, cause non  monotonic non  genomic 
dose–response patterns, typically having mul-
tiple dose optima. Interestingly, the very low 
concentration of BPA (10–14 M) caused a 
two-phased oscillating response rather like the 
alkyl  phenol XEs (Figures 1 and 2). However, 
1 nM BPA elicited a response more typical of 
the physiologic estrogen pattern (with three 
phases of activation).
Although we could choose a single health-
relevant level of physiologic estrogens based 
on their normal concentration ranges in ani-
mals and humans (Greenspan and Gardner 
2004), we felt it necessary to test many con-
centrations of the XEs to adequately describe 
the effects they might have at different com-
mon contamination levels, and to account 
for their non  monotonic behavior. We chose 
the 5-min time point for this study because 
of its prominent and consistent appearance 
in all physiologic estrogen and XE treatments 
(Figures 1–3) and because its rapid time frame 
ensured that it would result in a distinctly 
non  genomic response.
For most alkylphenols acting alone 
(EP, PP, and NP; Figures 4 and 5), signi  fi-
cant estrogenic effects occurred at the higher 
doses (usually picomolar or higher concen-
trations), but OP showed more activity at 
the lower doses. The short-chain EP caused 
greater stimulations than did all physiologic 
estrogens. PP caused marked non  monotonic 
dose responses, with effective doses peaking in 
both approximately pico  molar and nano  molar 
ranges. Alkylphenols generally enhanced phys-
iologic estrogen responses at lower doses but 
severely disrupted them at higher doses to far 
below vehicle control levels. EP was estrogenic 
over most of the tested concentration range 
and inhibited its paired physiologic estrogens 
throughout. PP was significantly estrogenic 
at two concentration ranges and lowered the 
estrogenicity of E2 and E1 beginning at the 
concentration at which it became estrogenic 
itself (approximately picomolar). However, PP 
enhanced the estrogenicity of E3 at all but the 
lowest tested concentrations (Figure 4F). This 
last result was the most signi  fi  cant departure 
from the general pattern and illustrates why 
each compound must be tested across its entire 
range to reveal such exceptions.
BPA showed the most striking non-
monotonicity in its dose–response pattern 
(Figure 6), as we have seen previously in this 
and other cell systems (Alyea and Watson 
2009a; Watson et al. 1999). The lowest 
BPA doses were very estrogenic, followed by 
a (generally) 2 log dose range of ineffective 
concentrations (10–100 pM), followed finally 
by another dose range of estrogenic activ-
ity (at nanomolar or higher concentrations). 
Remarkably, at whatever doses BPA was most 
estrogenic, it had the most marked inhibi-
tory effect on the estrogenicity of the paired 
physiologic estrogen. At doses where BPA was 
ineffective, the estrogenicity of the physiologic 
estrogen was spared (close to normal or, for 
E2, at least clearly above vehicle control values) 
or even enhanced (for E1 and E3).
To further characterize this response caused 
by all estrogens, we examined in more detail 
which of several ER proteins were responsible 
(Figure 7A–D). We again examined ERK acti-
vation after 5 min, as a distinct non  genomic 
response indicator. The selective ERα agonist 
PPT increased pERK levels over a wide range 
of concentrations (as low as 10–14 M), includ-
ing those highly selective for ERα. The ERβ 
agonist DPN had no effect at any selective con-
centration; it is known to be rather non  selective 
at higher levels (Meyers et al. 2001). The selec-
tive GPER agonist G1 increased pERK levels 
at relatively low concentrations (approximately 
picomolar) but decreased pERK at higher than 
nanomolar concentrations.
Because ERK activation is often associated 
with the proliferative response, we also used 
Figure 3. Time-dependent changes in pERK elicited by combinations of BPA at two different environmen-
tally relevant concentrations. GH3/B6/F10 cells were cotreated with 10–14 M BPA (A–C) or 10–9 M BPA 
(D–F) plus 1 nM E2 (A,D), E1 (B,E), or E3 (C,F). The pERK levels were measured after different times of 
cotreatment. 
*p < 0.05 compared with vehicle-treated control cells, shaded to match each set of data symbols (*, *, ✫). #p < 0.05 com-
pared with cells treated with 1 nM E2, E1, or E3 alone.
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these same receptor-selective compounds to 
evaluate their ability to evoke cell proliferation 
after 3 days of treatment (Figure 7E–H). At 
selective concentrations, both PPT and DPN 
caused cell proliferation, whereas G1 caused a 
decrease in cell numbers at all concentrations 
≥ 100 fM. In our side-by-side comparison, 
ERK activation correlated with the ability to 
affect proliferation reasonably well for PPT 
and negatively for G1 but did not correlate 
well with cell proliferation caused by DPN 
(which also did not selectively activate ERK). 
Because E2 activates all forms of ERs, it has a 
composite (positive) profile for inducing cell 
proliferation.
Discussion
Oscillating time-dependent and non  mono-
tonic concentration-dependent responses are 
typical for nongenomic estrogenic responses 
(Alyea et al. 2008; Watson et al. 2007a, 
2010; Zsarnovszky et al. 2005), and we again 
demonstrated such characteristics for this 
set of structurally related XEs of the alkyl-
phenol class. The complexities of fluctuating 
responses and their relationship to multiple 
signaling pathway involvement in the activa-
tion of ERKs by estrogens have only recently 
been appreciated. Such complications require 
that we develop methods to document differ-
ent functional and signaling outcomes quanti-
tatively, in order to establish the different 
potencies and temporal patterns evoked by 
XEs, as we did in this study. Our quantitative 
ERK activation assays allowed multiple com-
parisons between structurally related physio-
logic estrogens (E1, E2, E3) and an XE class 
(alkyl  phenols and BPA), and also allowed 
us to carefully docu  ment the combinatorial 
effects of XEs (both inhibiting and enhancing 
estrogenicity) on these physiologic estrogens 
that are functionally important to different 
life stages of women and men.
By themselves, all three physiologic estro-
gens, BPA, and alkylphenols were potent 
non  genomic response activators at the low 
concentrations tested, as we have seen previ-
ously (Alyea and Watson 2009a; Bulayeva and 
Watson 2004; Kochukov et al. 2009; Midoro-
Horiuti et al. 2010; Narita et al. 2007; 
Watson et al. 2008; Wozniak et al. 2005). 
In contrast, many past studies of genomic 
responses to these compounds (other than E2) 
showed them to be weak (Bonefeld-Jørgensen 
et al. 2007; Moon et al. 2007). Signaling or 
functional response profiles for different non-
genomic responses can vary markedly among 
estrogens (Borgert et al. 2003; Kochukov et al. 
2009; Routledge et al. 2000), as we demon-
strated again in this study, so each must be 
examined individually until such time as our 
structure–activity knowledge increases.
XEs have been shown to disrupt physio-
logic estrogenic responses in vivo (Alonso-
Magdalena et al. 2006; Midoro-Horiuti et al. 
2010). Testing of low, environmentally rele-
vant concentrations was prompted in many 
cases by the demonstration that they are active 
on cell signaling responses and functions 
in vitro (Alyea and Watson 2009a; Bulayeva 
and Watson 2004; Kochukov et al. 2009; 
Watson et al. 2007b; Wetherill et al. 2007; 
Wozniak et al. 2005). However, little is cur-
rently known about exactly how such complex 
signaling patterns are initiated by XEs. Their 
weak affinity profiles for the nuclear versions 
of ERs (Blair et al. 2000) are puzzling, given 
their potent actions via membrane versions of 
the same receptors. Binding of such lipophilic 
compounds to membrane-resident proteins 
is difficult to measure and interpret because 
of high backgrounds in the measurements 
and small populations of membrane-resident 
receptors (Nadal et al. 2000; Powell et al. 
1999), as well as possible binding to different-
shaped binding pockets. 
The estrogenicity of all physiologic estro-
gens examined in our assay was subject to 
similar disruptions by combination with 
XEs. Levels of pERK were either attenuated 
or potentiated, depending on the timing or 
concentration of the treatments, making clear 
the necessity of examining these parameters 
carefully for each compound. However, gen-
erally speaking, some overall principles were 
established. Whenever an XE caused a strong 
response (either at a particular time point or 
concentration), the paired physiologic estro-
gen response was inhibited; whenever an XE 
caused a weak or no response, its combination 
with physiologic estrogens usually caused a 
synergistic enhancement of pERK levels. This 
Figure 4. Concentration-dependent changes in pERK caused by short-chain alkylphenols. Cells were 
treated for 5 min with a combination of 1 nM E2 (A,D), E1 (B,E), or E3 (C,F) plus different concentrations of 
EP (A–C) or PP (D–F), and pERK was assayed. The blue horizontal bar indicates the pERK level and error 
range in vehicle-treated cells (V); the crosshatched horizontal bar indicates the pERK value in cells treated 
with nanomolar concentrations of E2, E1, or E3 alone. 
*p < 0.05 compared with vehicle-treated cells. #p < 0.05 compared with cells treated with E2, E1, or E3 alone.
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was particularly easy to observe for BPA, with 
its pronounced non  monotonic dose curve, 
but we also observed it in the responses to 
the other alkyl  phenols. Cotreatments often 
resulted in out-of-phase oscillations compared 
with those caused by individual estrogens, 
with apparent shifts to later response times 
and less frequent oscillations. In another 
(neuronal) cell type exhibiting a different 
functional response (dopamine efflux), we saw 
a similar pattern, especially with low concen-
trations of XEs in combination with E2 (Alyea 
and Watson 2009a).
We used very low doses of BPA in the 
present study compared with many others in 
the literature; this emphasizes the toxicity that 
can be caused by levels commonly present 
in our environment and food. BPA potenti-
ated ERK activation at levels as low as pico-
molar concentrations, whereas femtomolar 
and nanomolar BPA generally disrupted all 
physiologic estrogen-induced ERK activities. 
Changes seen in later (60 min) ERK activa-
tion with several estrogen/XE combinations 
may indicate functional consequences for reg-
ulating cell prolifera  tion (Razidlo et al. 2004; 
Yang et al. 2008) and other epi  genetic aspects 
of carcino  genicity (Bredfeldt et al. 2010). 
Even though we tested some responses only at 
short exposure times to emphasize the rapid 
nature of these activations and disruptions, 
such stimuli would undoubtedly be sustained 
or repeated, because these compounds gener-
ally persist both in fat stores and in the envi-
ronment (Calafat et al. 2005; Ye et al. 2006).
Using selective ER agonists, we found that 
ERα activation was the dominant mediator of 
the pERK level increases, whereas ERβ had no 
effect. The activation by the selective GPER 
agonist G1 is difficult to interpret because it 
caused a biphasic activation of ERK, being 
stimulatory only at very low concentrations 
(femtomolar to picomolar) but inactivat-
ing ERK at picomolar to nanomolar ranges. 
Although natural ligands (other than the non-
selective E2) are not known for GPER, these 
data suggest an inhibitory role for GPER at 
what would be an expected physiologic con-
centration of hormone acting on adult tissue 
(up to nanomolar concentrations). GPER’s 
sensitive activation by G1 does not match what 
is known about its affinity for G1 and its acti-
vation of other functional end points (Bologa 
et al. 2006; Filardo et al. 2000; Prossnitz and 
Maggiolini 2009; Thomas et al. 2005). Could 
this indicate an important role for GPER in 
Figure 5. Concentration-dependent changes in pERK caused by the long-chain alkylphenols. Cells were 
treated for 5 min with a combination of 1 nM E2 (A,D), E1 (B,E), or E3 (C,F) plus different concentrations of OP 
(A–D) or NP (D–F), and pERK was assayed. The blue horizontal bar indicates the pERK level and error range in 
vehicle-treated cells (V); the crosshatched horizontal bar indicates the pERK value in cells treated with nano-
molar concentrations of E2, E1, or E3 alone. 
*p < 0.05 compared with vehicle-treated cells. #p < 0.05 compared with cells treated with E2, E1, or E3 alone.
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other, less-studied scenarios such as develop-
mental signaling, where hormonal levels gener-
ally rise from non  existent to initially quite low 
levels to trigger tissue remodeling? Do cultured 
cancer cells exhibit receptor subtypes and sen-
sitive responses that are generally more com-
mon to developmentally immature cells and so 
have an exaggerated GPER response? Finally, 
there are now reports that G1 is actually a 
ligand for an alternatively spliced/truncated   
form of ERα (ERα36) that inter  acts with 
GPER, but not for GPER itself (Kang et al. 
2010), and that this form is involved in the 
activation of ERKs. Interestingly, our data 
show activation via both ERα and GPER 
(but not ERβ) and do not exclude the inter-
pretation that G1 acts via ERα36 in our cell 
line. Antibodies that we have used in the 
past to identify mERα on these cells and to 
select high expressers [e.g., H222; (Pappas 
et al. 1995a, 1995b)] also recognize ERα36, 
and our immuno  blots of membrane proteins 
with H222 show multiple immuno  reactive 
proteins, including one that is 36 kDa (data 
not shown). Thus, our cell line probably also 
expresses this form.
Estrogens and XEs cause these cells to 
proliferate and also activate ERKs and other 
MAPKs, as we have shown previously (Jeng 
and Watson 2009; Kochukov et al. 2009; 
Watson et al. 2008), although some phyto-
estrogens inhibit proliferation when combined 
with physiologic estrogens (Jeng et al. 2010; 
Jeng et al. 2009). Often ERKs are desig  nated 
as the MAPKs most responsible for cell prolif-
eration, with some exceptions to this generali-
za  tion (Zhou et al. 2007). In the present study 
the ERα-selective ligand PPT caused both 
ERK phosphorylation and proliferation, con-
sistent with that hypothesis, whereas selective 
GPER liganding mostly inhibited both pro-
cesses at expected physiologic concentrations. 
Although the ERβ ligand did not evoke an 
ERK response at selective concentrations, it 
was still capable of causing some cell prolifera-
tion at a wide range of concentrations, some 
selective. Clearly, these considera  tions are 
more complicated than we usually summarize 
them to be. The balance of different kinds of 
MAPKs activated by these compounds could 
tell a more complete story, because some-
times the ability of estrogens to activate ERKs 
1 and 2 compared with other ERKS, c-Jun 
N-terminal kinases (JNKs) and p38 differ.
Phosphorylation of cellular ERKs is a 
dynamic process, involving multiple pathways 
and regulators in complicated time- and con-
centration-dependent patterns, creating oscil-
lating ERK (and other MAPK) activations. 
MAPKs serve as signal integrators in most tis-
sues (Watson et al. 2010), and examples of the 
details of this kind of regulation will probably 
be tissue specific. We have shown in the past 
that these signal cascades can travel down their 
pathways at different speeds, arriving at the 
final node (activated ERK) at different times 
(Bulayeva and Watson 2004). Summation of 
an early arrival at this end point with a later 
one, with no signals arriving in between, could 
generate a summed response that oscillates. 
Similarly, low- versus high-dose responses trig-
gering different signaling pathways could also 
sum to an overall non  monotonic curve. It is 
also likely that phosphatases may be specifically 
activated by estrogens, although this mech-
anism is still largely undefined (Fujita et al. 
2010; Zivadinovic and Watson 2005), or other 
receptors might contribute. Oscillating tempo-
ral patterns can encode important information 
for some hormonal responses (e.g., growth hor-
mone, gonadotropins). A role for information-
rich oscillating patterns of different frequency 
and amplitude has recently been suggested for 
phosphorylations of signaling kinases and their 
targets (Fujita et al. 2010).
Exposed human and animal populations 
will probably have windows of vulnerability 
based on sex, life stage, and tissue differences 
in the expression and activities of the ERs 
involved in these actions. We have examined 
only limited cases, where ERα and perhaps 
GPER are involved in causing some kinase 
Figure 7. Concentration dependence of pERK (A–D) and proliferation (E–H) on selective ER agonists. pERK 
was measured in cells after 5 min of treatment with different concentrations of E2 (A), the ERα agonist 
PPT (B), the ERβ agonist DPN (C), or the GPER agonist G1 (D). Proliferation was measured (via the crystal 
violet assay) in cells treated for 3 days with matching concentrations of E2 (E), PPT (F), DPN (G), or G1 (H). 
V, vehicle-treated cells. 
*p < 0.05 compared with vehicle-treated cells.
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activations/deactivations. However, many 
other estrogen-induced signaling cascades 
(Belcheva and Coscia 2002; Watson and 
Gametchu 2003) need to be investigated in 
similar detail to be able to start generalizing 
about the mechanisms of endocrine disruption 
caused by XEs of particular structural classes.
co r r e c t i o n
In Figures 5 and 6 in the original manu-
script published online, the figures were cor-
rect but the wrong cell treatments were listed 
in the figure legends. The figure legends have 
been corrected here. 
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